Cochlear appoints two new directors
Cochlear Limited (ASX:COH) has appointed two experienced new directors to its board.
The cochlear implant provider has announced that Alison Deans and Glen Boreham will both join the board as non-executive directors starting 1 January.
Deans has had a more than 20-year career in senior management and consulting roles, including as CEO of eCorp, Hoyts Cinemas and eBay Australia and New Zealand. She was most recently CEO of technology investment company netus before it was acquired by Fairfax in 2012.
She currently also serves on the boards of Westpac, Insurance Australia Group and kikki.K Holdings.
Boreham has held senior executive roles at companies including IBM Australia and New Zealand, and is currently a non-executive director of Data#3. He is also chair of the industry advisory board for the UTS.
“Alison is clearly a very smart and articulate person, she is a strategic thinker with extensive experience in digital businesses that, together with her accomplished career in senior leadership roles, make her a valuable addition to the Cochlear board,” chairman Rick Holliday-Smith said.
“Glen’s experience in a major technology corporation and understanding of technology and innovation makes him [another] important addition to the board.”
Cochlear (ASX:COH) shares were trading 0.78% higher at $73.470 as of around 12 pm on Tuesday.
How a common gene mutation increases liver disease risk
Liver damage can be caused in people after exposure to high levels of acrolein, especially in...
Gene therapy slows Huntington's disease progression in trial
Patients receiving the treatment were found to experience 75% less progression of the disease...
AI-driven manufacturing: lessons from the life sciences industry
The use of artificial intelligence for batch monitoring and digital twin development is...
